Cita APA

N, P., A, T., LV, S., G, P., Q, W., L, A., . . . J, Z. (2025). COMPEL: Osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib.

Citación estilo Chicago

N, Peled, et al. COMPEL: Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-mutated Advanced NSCLC and Progression On First-line Osimertinib. 2025.

Cita MLA

N, Peled, et al. COMPEL: Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-mutated Advanced NSCLC and Progression On First-line Osimertinib. 2025.